FI954347A - Monoklonala antikroppskompositioner och hybridomer som producerar monoklonala antikroppar - Google Patents

Monoklonala antikroppskompositioner och hybridomer som producerar monoklonala antikroppar Download PDF

Info

Publication number
FI954347A
FI954347A FI954347A FI954347A FI954347A FI 954347 A FI954347 A FI 954347A FI 954347 A FI954347 A FI 954347A FI 954347 A FI954347 A FI 954347A FI 954347 A FI954347 A FI 954347A
Authority
FI
Finland
Prior art keywords
monoclonal antibodies
antibody compositions
hybridomas producing
monoclonal antibody
monoclonal
Prior art date
Application number
FI954347A
Other languages
English (en)
Finnish (fi)
Other versions
FI97813C (sv
FI954347A0 (sv
FI97813B (sv
Inventor
Thomas S Edgington
James H Morrissey
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27364291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI954347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/067,103 external-priority patent/US5110730A/en
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI954347A publication Critical patent/FI954347A/sv
Publication of FI954347A0 publication Critical patent/FI954347A0/sv
Application granted granted Critical
Publication of FI97813B publication Critical patent/FI97813B/sv
Publication of FI97813C publication Critical patent/FI97813C/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI954347A 1987-03-31 1995-09-15 Monoklonala antikroppskompositioner och hybridomer som producerar monoklonala antikroppar FI97813C (sv)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US3304787A 1987-03-31 1987-03-31
US3304787 1987-03-31
US07/067,103 US5110730A (en) 1987-03-31 1987-06-25 Human tissue factor related DNA segments
US6710387 1987-06-25
US16593988 1988-03-09
US07/165,939 US5223427A (en) 1987-03-31 1988-03-09 Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US8800998 1988-03-29
PCT/US1988/000998 WO1988007543A1 (en) 1987-03-31 1988-03-29 Human tissue factor related dna segments, polypeptides and antibodies
FI885543A FI100184B (sv) 1987-03-31 1988-11-29 DNA-segment och rekombinant DNA-molekyl anslutande till human vävnadsf aktor samt förfarande för framställning av ett protein
FI885543 1988-11-29

Publications (4)

Publication Number Publication Date
FI954347A true FI954347A (sv) 1995-09-15
FI954347A0 FI954347A0 (sv) 1995-09-15
FI97813B FI97813B (sv) 1996-11-15
FI97813C FI97813C (sv) 1997-02-25

Family

ID=27364291

Family Applications (2)

Application Number Title Priority Date Filing Date
FI885543A FI100184B (sv) 1987-03-31 1988-11-29 DNA-segment och rekombinant DNA-molekyl anslutande till human vävnadsf aktor samt förfarande för framställning av ett protein
FI954347A FI97813C (sv) 1987-03-31 1995-09-15 Monoklonala antikroppskompositioner och hybridomer som producerar monoklonala antikroppar

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI885543A FI100184B (sv) 1987-03-31 1988-11-29 DNA-segment och rekombinant DNA-molekyl anslutande till human vävnadsf aktor samt förfarande för framställning av ett protein

Country Status (13)

Country Link
US (2) US5223427A (sv)
EP (2) EP0309548B1 (sv)
JP (1) JP2809415B2 (sv)
AT (1) ATE246200T1 (sv)
AU (1) AU605864B2 (sv)
CA (1) CA1340544C (sv)
DE (1) DE3856560T2 (sv)
DK (1) DK175703B1 (sv)
ES (1) ES2009590A6 (sv)
FI (2) FI100184B (sv)
NO (1) NO305211B1 (sv)
PT (1) PT87138B (sv)
WO (1) WO1988007543A1 (sv)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US7084251B1 (en) 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
DK299889A (da) * 1988-06-17 1989-12-18 Sinai School Medicine Kloning og ekspression af human vaevsfaktor
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5314695A (en) † 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US6203816B1 (en) * 1990-11-13 2001-03-20 Corvas International, Inc. Tissue factor based prothrombin time reagent
AU658604B2 (en) * 1991-01-10 1995-04-27 Teijin Limited Highly sensitive assay of tissue factor and kit therefor
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5879677A (en) * 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
US20010048924A1 (en) * 1998-06-22 2001-12-06 Del Zoppo Gregory J. Method for inhibiting cerebral tissue factor mediated reperfusion damage
JPH09504554A (ja) * 1993-12-27 1997-05-06 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント，インコーポレーテッド 血栓形成を阻止する方法及び組成物
JP4423680B2 (ja) * 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
US5837684A (en) * 1995-06-07 1998-11-17 Nycomed Imaging As Peptides
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
KR100565883B1 (ko) * 1997-01-22 2006-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 응고 및 종양 치료용 조직 인자 방법 및 조성물
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20040229282A1 (en) * 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
DE69832628T2 (de) * 1997-04-23 2006-09-07 Instrumentation Laboratory S.P.A. Rekombinant-kaninchengewebefaktor basiertes prothrombinzeitreagenz
PL343322A1 (en) * 1998-04-03 2001-08-13 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
ES2188202T3 (es) 1998-07-13 2003-06-16 Univ Texas Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
WO2000004148A1 (en) 1998-07-15 2000-01-27 Genentech, Inc. Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia
US7764130B2 (en) * 1999-01-22 2010-07-27 Multigig Inc. Electronic circuitry
EP1222854B1 (en) 1999-10-01 2011-02-16 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6703494B2 (en) * 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6855509B2 (en) * 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US20030143225A1 (en) * 2001-03-08 2003-07-31 Genentech, Inc. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
US20030129193A1 (en) * 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
CA2460917A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
IL161408A0 (en) * 2001-10-15 2004-09-27 Chiron Corp Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
ATE489103T1 (de) * 2001-10-26 2010-12-15 Scripps Research Inst Gezielte thrombose durch gewebefaktor polypeptiden
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
MXPA04010851A (es) 2002-05-01 2005-02-14 Schering Ag Proteinas de fusion de trombomodulina dirigidas al factor tisular novedoso como anticoagulantes.
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
US20050106139A1 (en) * 2002-10-31 2005-05-19 Ivan Svendsen Humanized tissue factor antibodies
US20040198660A1 (en) * 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
EP1587549A2 (en) * 2003-01-22 2005-10-26 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
KR20060035608A (ko) * 2003-05-30 2006-04-26 센토코 인코포레이티드 항 조직 인자 항체로 종양 성장을 저해하는 방법
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1644039B1 (en) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
EP1667718A4 (en) * 2003-08-29 2007-05-02 Centocor Inc METHOD FOR STIMULATING THE SURVIVAL OF A GRAFT WITH ANTI-TISSUE FACTOR ANTIBODY
JP2007532486A (ja) * 2004-03-17 2007-11-15 カイロン コーポレイション 組織因子経路インヒビターの投与による重度の市中肺炎の処置
US7790405B2 (en) * 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
US7514539B2 (en) * 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
WO2005117969A2 (en) * 2004-04-26 2005-12-15 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
WO2005118646A2 (en) * 2004-04-26 2005-12-15 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2380905A1 (en) 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof
AU2011267106B2 (en) * 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
WO2012033518A1 (en) * 2010-09-09 2012-03-15 The Scripps Research Institute Methods and compositions for treating metabolic disorders
US8722044B2 (en) * 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
ES2690557T3 (es) 2011-06-02 2018-11-21 University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
CN103566378B (zh) * 2013-09-09 2016-09-14 南京海智生物工程有限公司 基于组织因子的肿瘤核酸疫苗、制备方法及其应用
US10617764B2 (en) * 2013-11-21 2020-04-14 Genmab A/S Lyophilized anti-tissue factor antibody-drug conjugates
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
KR101989954B1 (ko) * 2017-10-16 2019-06-17 고려대학교 산학협력단 돼지 조직인자 세포외 도메인 단백질을 특이적으로 인식하는 단일클론항체 및 이의 용도
SG11202006400UA (en) * 2018-01-04 2020-08-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548904A (en) * 1982-12-03 1985-10-22 Molecular Genetics Research & Development Protein sequencing method
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
AU1948388A (en) * 1987-06-12 1989-01-04 Mount Sinai School Of Medicine Of The City University Of New York, The Cloning and expression of human tissue factor

Also Published As

Publication number Publication date
EP1364969A3 (en) 2004-12-29
PT87138A (pt) 1988-04-01
PT87138B (pt) 1992-07-31
NO885326D0 (no) 1988-11-29
FI885543A (fi) 1988-11-29
FI97813C (sv) 1997-02-25
EP1364969A2 (en) 2003-11-26
DE3856560D1 (de) 2003-09-04
ATE246200T1 (de) 2003-08-15
FI954347A0 (sv) 1995-09-15
WO1988007543A1 (en) 1988-10-06
ES2009590A6 (es) 1989-10-01
JP2809415B2 (ja) 1998-10-08
US5622931A (en) 1997-04-22
DK666888A (da) 1989-01-31
DK175703B1 (da) 2005-01-24
NO885326L (no) 1989-01-30
EP0309548A1 (en) 1989-04-05
EP0309548A4 (en) 1991-08-07
AU1627488A (en) 1988-11-02
NO305211B1 (no) 1999-04-19
FI885543A0 (fi) 1988-11-29
EP0309548B1 (en) 2003-07-30
JPH01503438A (ja) 1989-11-22
FI97813B (sv) 1996-11-15
AU605864B2 (en) 1991-01-24
DK666888D0 (da) 1988-11-29
US5223427A (en) 1993-06-29
CA1340544C (en) 1999-05-18
DE3856560T2 (de) 2004-08-05
FI100184B (sv) 1997-10-15

Similar Documents

Publication Publication Date Title
FI954347A (sv) Monoklonala antikroppskompositioner och hybridomer som producerar monoklonala antikroppar
DE69000338D1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
ATE142645T1 (de) Rezeptoren für wachstumshormone
ATE132197T1 (de) Monoklonale antikörper
HUP0100436A2 (hu) Emlős citokinszerű polipeptid-10
ATE88572T1 (de) Antikoerper gegen polypeptide, die gegen peptide oder proteine mit mindestens teilweise bekannter aminosaeure oder kodierender nukleotidsequenz komplementaer sind und diesbezuegliches aufbauverfahren.
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
DE69028513T2 (de) Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
DE3867537D1 (de) Mischung von monoklonalen antikoerpern zur bestimmung der creatinkinaseaktivitaet.
ES2149159T3 (es) Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion.
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
ATE50458T1 (de) Bestimmung von fibrin mit fibrin-spezifischen antikoerpern.
DE3787706T2 (de) Verfahren zur quantitativen Bestimmung der Antigene und Antikörper.
ATE137864T1 (de) Immunobestimmung von menschlichem osteocalcin, reagenz und satz dafür
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ES545128A0 (es) Procedimiento para preparar nuevos anticuerpos monoclonales de raton con especificidad anti-interferon de humano
ATE86261T1 (de) Tumorassoziiertes antigen.
EP0251186A3 (en) Monoclonal antibody to human plasminogen, method for production thereof, assay reagent and kit comprising said antibody, and hybridoma producing said antibody
NZ228194A (en) Monoclonal antibodies which bind to the n-terminal peptide sequence of the betasubunit of human haemoglobiin

Legal Events

Date Code Title Description
BB Publication of examined application
MA Patent expired